List of Studies ( Metabolite:Pro-His)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
|---|---|---|---|---|---|---|---|
| ST002787 | AN004534 | Metabolomic analysis of gut metabolites in colorectal cancer patients: correlation with disease development and outcome | Feces | Human | Cancer | Wuhan University of Science and Technology | Peak Area |
| ST002926 | AN004798 | Multi-“omics” analysis reveals the orphan P. falciparum protein kinase PfPK8 regulates multi-gene family expression | Blood | Plasmodium falciparum | Malaria | Monash University | peak height |
| ST003036 | AN004977 | Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 | Bacterial cells | Pseudomonas aeruginosa | Bacterial infection | Monash Institute of Pharmaceutical Sciences | peak height |
| ST003053 | AN005007 | Providing insight into the mechanism of action of Cationic Lipidated Oligomers (CLOs) using metabolomics | Bacterial cells | Staphylococcus aureus | Bacterial infection | Monash University | peak height |
| ST003144 | AN005159 | On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity | Blood | Plasmodium falciparum | Malaria | Monash University | peak height |
| ST003521 | AN005782 | Metabolic Profiling Unveils Enhanced Antibacterial Synergy of Polymyxin B and Teixobactin against Multi-Drug Resistant Acinetobacter baumannii | Bacterial cells | Acinetobacter baumannii | Bacterial infection | Monash University | peak height |
| ST003179 | AN005221 | Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4 | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | Peak height |
| ST000421 | AN000663 | ms3076 T1D poor glycemic control and control samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
| ST000421 | AN000665 | ms3076 T1D poor glycemic control and control samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
| ST000422 | AN000667 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
| ST000422 | AN000669 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
| ST001201 | AN001999 | Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | Peak intensity |
| ST001201 | AN001999 | Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | Peak intensity |
| ST002094 | AN003420 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | raw intensity |
| ST000046 | AN000076 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
| ST000046 | AN000077 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
| ST000047 | AN000080 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
| ST000047 | AN000081 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
| ST002106 | AN003445 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 1) | Blood | Plasmodium falciparum | Malaria | Monash University | relative intensity |
| ST002107 | AN003446 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 2) | Blood | Plasmodium falciparum | Malaria | Monash University | relative intensity |
| ST002108 | AN003448 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) | Blood | Plasmodium falciparum | Malaria | Monash University | relative intensity |
| ST002309 | AN003771 | Targeting malaria parasites with novel derivatives of azithromycin | Blood | Plasmodium falciparum | Malaria | Monash University | relative intensity |
| ST002512 | AN004136 | Gnotobiotic mice: Metabolites in intestinal contents of germ-free mice colonized with strains of gut bacterium Eggerthella lenta | Intestine | Mouse | University of California, San Francisco | relative ion counts | |
| ST001315 | AN002189 | Retargeting azithromycin-like compounds as antimalarials with dual modality | Blood | Plasmodium falciparum | Malaria | Monash University | Signal Intensity |
